女性急性冠脉综合征抗栓治疗:性别调整策略与女性在随机临床试验中的代表性
该临床共识声明由EAPCI与ESC血栓工作组制定,指出女性在ACS中院内侵入性操作相关出血及长期院外出血风险高于男性,且未按体重或肾功能调整抗栓药物剂量更常增加女性出血风险。声明强调需提高对性别特异性风险与偏倚的认识,优化性别调整的抗栓治疗以减少结局差异。
要点
- 女性ACS患者院内侵入性操作相关出血及长期院外出血风险高于男性。
- 未按体重或肾功能调整抗栓药物剂量更常与女性出血风险增加相关。
- ACS研究中抗栓药物疗效无性别差异,但女性可能因转诊、诊断及侵入性治疗决策偏倚而延迟治疗。
核心结论
- 女性ACS患者出血风险高于男性,需关注性别特异性出血缓解策略及特殊情况下抗栓管理。
- 抗栓药物疗效无性别差异,但女性可能因诊疗偏倚延迟治疗,需优化性别调整的抗栓治疗。
研究设计与样本
- 欧洲经皮心血管介入协会(EAPCI)与ESC血栓工作组联合制定的临床共识声明,基于现有最佳证据提供专家意见与共识声明。
主要发现
- 与男性相比,女性院内侵入性操作相关出血风险及长期院外出血事件风险增加。
- 未根据体重或肾功能调整抗栓药物剂量更常与女性出血风险增加相关。
- ACS研究支持抗栓药物疗效无性别差异,但女性可能因转诊、诊断和侵入性治疗决策偏倚而延迟治疗。
关键数值与推荐
- 女性经历与月经周期、口服避孕药、激素替代治疗或绝经相关的促血栓与出血状态频繁波动。
- 临床研究常低估女性代表性,但现有数据一致支持基线血栓与出血风险存在性别特异性差异。
临床怎么用
- 提高对ACS管理中性别特异性风险与偏倚的认识。
- 关注性别特异性出血缓解策略。
- 优化特殊情况下(如非阻塞性冠状动脉心肌梗死)的抗栓管理。
- 关注女性在心血管试验中代表性的障碍。
局限性
- 临床研究常低估女性代表性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thrombotic and bleeding risks differ between sexes, partly in relation to distinct biology and hormonal status, but also due to differences in age, comorbidities, and body size at presentation. Women experience frequent fluctuations of prothrombotic and bleeding status related to menstrual cycle, use of oral contraceptives, hormone replacement therapy, or menopause. Although clinical studies tend to underrepresent women, available data consistently support sex-specific differences in the baseline thrombotic and haemorrhagic risks. Compared with men, women feature an increased risk of in-hospital bleeding related to invasive procedures, as well as long-term out-of-hospital bleeding events. In addition, the inappropriate dosing of antithrombotic drugs, which is not adapted to body weight or renal function, is more frequently associated with an increased risk of bleeding in women compared to men. While acute coronary syndrome (ACS) studies support similar antithrombotic drug efficacy, irrespective of sex, women may receive delayed treatment due to bias in their referral, diagnosis, and invasive treatment decisions. The current clinical consensus statement highlights the need for an increased awareness of sex-specific risks and biases in ACS management, with a focus on sex-specific bleeding mitigation strategies, antithrombotic management in special conditions (e.g., myocardial infarction with non-obstructive coronary arteries), and barriers to female representation in cardiovascular trials. This manuscript aims to provide expert opinion, based on the best available evidence, and consensus statements on optimising antithrombotic therapy according to sex, which is critical to improve sex-based disparities in outcome.
引用
- Paradies, Masiero, Rubboli, et al. Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis. Eur Heart J. 2025. PMID: 40390370. doi:10.1093/eurheartj/ehaf352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。